"First offer" Bomi Medical completed hundreds of millions of dollars of C round of financing, by Gao Wei, Kaihui, the Service Trade Fund investment.

Guide: Bomai Medical this round of financing only time can not find April, admirable!---- Recently, Guangdong Bomi Medical Devices Co., Ltd(hereinafter referred to as "Bomei Medical") announced the completion of hundreds of millions of yuan of C round financing, this financing by Gaohao Ventures, Kaihui Fund, Service Trade Fund and investment, Hao Yue Capital as the sole financial adviserAs a domestic technology and scale-leading coronary and peripheral cystic catheter national brand, Bomi Medical this round of financing took less than four months to complete quickly, especially in the new crown outbreak of severe challenges, such efficiency and achievements are even more valuableBomi Medical is a medical high-value consumables research and development manufacturers, its product line includes cardiovascular intervention products, peripheral vascular intervention products, neuro-intervention products and accessories products four categories of nearly a thousand products and combinationsBomi Medical hopes to combine the world's leading product and manufacturing process technologies with innovative and open business models to consolidate and enhance the competitive position of domestic brands in the global high-end medical device consumables marketThe big market out of large-cap enterprises, optimistic about Bomi medical core technology platform, why is it optimistic about vascular intervention in the field of high-value consumables? IVD, cardiovascular, imaging, orthopaedics, and ophthalmology are the largest areas in the global market, according to the report "Evaluate MedTech, WorldPreview2018, Outlookto2024" published by the global consulting firm EvaluateMedtronic, Johnson and Johnson, Danaher, Beatty and other global market value TOP10 equipment enterprises, the main business is also concentrated in cardiovascular, orthopaedic and IVD and other fields, which proves that the large market size of the field is easier to produce large market cap companiesAccording to Haitong Securities' report "The Golden Age of Devices: The Rise of Local Innovation", minimally invasive interventional therapy is one of the innovative directions of domestic devices in the futureIn 2007, China carried out a total of 143,000 cases of PCI, during the same period, 18,000-2000 cases of coronary bridgeBomei Medical revealed that in 2019 a total of 1.07 million cases of PCI, balloon catheter use of more than 2 million sets, PCI growth rate is much faster than coronary bypassThe rapid growth of the amount of minimally invasive interventional surgery has increased the market penetration rate of related medical devices and high-value consumables, and has also cultivated the market, laying the foundation for the outbreak of minimally invasive interventional therapy marketThe explosion of the minimally invasive interventional therapy market will create a huge market for high-value consumables, and the future of this sector will also be the birth of large-cap companiesWhy is it optimistic about Bomi Medical? Bomei Medical, as a leading enterprise in the domestic vascular intervention balloon catheter market industry, has established the Guangdong Vascular Intervention Treatment and Medical Device Engineering Technology Center and Dongguan City Vascular Intervention algeunos medical device research and development key laboratoryAfter nearly a decade of development and nearly two decades of technology accumulation, Bomi Medical is on the global market products have been involved in three major areas, more than a dozen categories, and research and development projects are also double-digitWith its global exclusive technology, Bomi Medical has built an international technology and product development platform dominated by advanced vascular intervention medical device technologyAt the same time, Bomi Medical's innovation team continuously updates its iteration products with continuous research and development capabilitiesOn February 19, 2020, Bomi Medical three represent sac catheter international advanced technology and unique and innovative products, on the same day received the CE certificate approval of the European Union certification body, landing in the European Union and related regional marketsThree products, high technology gold content and innovationAlveo (TM) the world's smallest CTO coronary ball (0.75mm) and Tri-Wedge (TM) three-conductor engraved ball sac catheters are the world's original patented products, representing the latest cutting-edge technological innovations in this field, while Wedge (TM) NC high-pressure non-conforming nick balloon catheters also have exclusive patent edifyingThis result also demonstrates The continued innovation capabilities of Bomi Medical's advanced technology platform and team(Enterprise supply) It is understood that Bomi Medical's coronary cystic catheter and peripheral cystic catheter are so far, China's national brands, the only one in the United States, Japan and the European Union three major medical developed countries and regions have achieved the scale of market sales of high-end medical device productsBomei's products from the beginning of the market sales to now only 5 years, but has been exported to more than 40 countries and regions, in some countries have achieved double-digit market share, breaking the advantages of international giants technical barriers and market monopolyAnd in the return to the Chinese market listed in less than three years, but also to double the annual growth rate, quickly become the domestic coronary cystic catheter market leader, favored by clinicians and the market"The high-end medical device industry needs not only the spirit of innovation that needs to be explored and dared to break through, but also the quality of the craftsman who is down-to-earth and strives for excellence, " says GaoOver the years, Bomi Medical adheres to research and development investment, deep-cultivated vascular intervention balloon catheter market, and constantly introduce high-end medical device products with international advanced technology level, in the field of vascular intervention medical devices raised the 'Created in China' brandGaogao Ventures wants to support Bomi Healthcare, moving toward the peak of vascular intervention altimely medical technology, bringing more surprises and boon to doctors and patients through continuous innovationThe China Trade Fund is also confident about the future of Bomai, said Dong Jiaxuan of the China Trade Fund: "The National Trade Fund was jointly initiated by the Ministry of Finance and the Ministry of Commerce of the People's Republic of China to support Chinese service enterprises to improve their international competitiveness." Bomi Medical has an international perspective and participate in the technical basis of international competition, the Food and Trade Fund will fully play the national fund's policy leadership advantages, help Bomi Medical to continue to grow in scale and upgrade the technical level, in the rapid realization of domestic substitution in related areas at the same time, continue to expand the international market, and gradually grow into the world's leading high-tech medical enterprises"Bomai Medical is a high-quality medical device company with potential, especially in February this year, when the company's three products representing vascular intervention almost international advanced technology and unique innovation capabilities were approved by CE certificate at the same time, which is remarkable." We are optimistic about the development prospects of Bomi as a high-end medical device manufacturer driven by research and development"About Bomi Medical Bomi Medical was established in 2012, the global headquarters in Dongguan, Guangdong Songshan Lake, mainly engaged in balloons, catheters, wire and accessories as the core (heart) vascular intervention three types of medical device research and development and productionAfter eight years of development, Bomi Medical has grown into a domestic vascular intervention high-value supplies in the field of technology and scale leading national enterprises, with cardiovascular intervention, peripheral vascular intervention, vascular pathways and intervention accessories category of four major product families nearly 20 series, thousands of products, products are exported to the United States, Japan, the European Union and other countries around the world more than 40 countriesThe company has several new and innovative global products and technologies, including the world's smallest CTO coronary dilated cyatic catheter (0.75mm), tri-wire nick cyalot catheter, and "zero powder" drug cyalot catheterAbout Gaoyu Ventures is a venture capital fund focused on early innovative companies, focusing on biopharmaceutical and medical devices, software services and primary technology innovation, consumer Internet and technology, emerging consumer brands and services Biomedicine and medical devices have been the focus of investment direction, has nearly 15 years of in-depth research, has invested in more than 160 outstanding pharmaceutical, equipment enterprises, including Baiji Shenzhou, Cinda Biology, Junshi Bio, Tianyi Biology, Fonda Pharmaceuticals, Namicro Technology, McCortian Medical, Pyeke Medical, Puss Medicine, Pejia Medical, Micro-Creative Heart, Kaiming Medical and so on We hope to work with investment companies to be friends of time, and jointly promote the innovation and development of enterprises in the field of health, benefiting more patients As an international leader private equity fund focused on cross-border investments, Kaihui Fund has supported innovation and the growth and internationalization of small and medium-sized enterprises in China, Europe, North America, Africa and Southeast Asia since its inception in 2006, and is committed to becoming the most industrial resource and financial investor with industry insight Fund asset management scale of 3.5 billion euros, more than 150 enterprises invested in the world, focusing on consumer, TMT, healthcare, automotive travel, energy, fintech, high-end manufacturing and other fields, has excavated and invested in Sofia, Zhibang home, Big Year Health, love recycling and other dozens of high-quality enterprises, as well as Momenta, Pedor, Drivy, Glovo, Chime and other star unicorn projects, accompanied by their growth into leading industries About THE TRADE AndTrade Fund Service Trade Innovation and Development Guidance Fund (Limited Partnership) is a fund of China Merchants Capital China Merchants Capital was established in 2012 as a joint venture between China Merchants Group and Poulos, specializing in alternative investment and asset management By the end of 2019, China Merchants Capital managed total assets of about 270 billion yuan China Merchants Capital ranks 13th in the top 50 private equity institutions in China in 2019